BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17581615)

  • 21. Direct detection of a BRAF mutation in total RNA from melanoma cells using cantilever arrays.
    Huber F; Lang HP; Backmann N; Rimoldi D; Gerber Ch
    Nat Nanotechnol; 2013 Feb; 8(2):125-9. PubMed ID: 23377457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens.
    Dominguez PL; Kolodney MS
    Oncogene; 2005 Oct; 24(45):6830-4. PubMed ID: 16116485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assaying for BRAF V600E in tissue and blood in melanoma.
    Panka DJ; Mier JW; Sullivan RJ
    Methods Mol Biol; 2014; 1102():117-36. PubMed ID: 24258977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
    Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
    Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
    Shinozaki M; O'Day SJ; Kitago M; Amersi F; Kuo C; Kim J; Wang HJ; Hoon DS
    Clin Cancer Res; 2007 Apr; 13(7):2068-74. PubMed ID: 17404088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid detection of mutations in the BRAF gene using real-time polymerase chain reaction and melting curve analysis.
    Ikenoue T; Hikiba Y; Kanai F; Ijichi H; Togo G; Ohta M; Watabe H; Yamaji Y; Okamoto M; Aragaki J; Matsumura M; Kawabe T; Omata M
    Cancer Genet Cytogenet; 2004 Feb; 149(1):68-71. PubMed ID: 15104286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
    Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
    Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms.
    Miller CJ; Cheung M; Sharma A; Clarke L; Helm K; Mauger D; Robertson GP
    J Invest Dermatol; 2004 Nov; 123(5):990-2. PubMed ID: 15482489
    [No Abstract]   [Full Text] [Related]  

  • 31. Competitive amplification of differentially melting amplicons (CADMA) enables sensitive and direct detection of all mutation types by high-resolution melting analysis.
    Kristensen LS; Andersen GB; Hager H; Hansen LL
    Hum Mutat; 2012 Jan; 33(1):264-71. PubMed ID: 21901793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients.
    Stadler J; Eder J; Pratscher B; Brandt S; Schneller D; Müllegger R; Vogl C; Trautinger F; Brem G; Burgstaller JP
    PLoS One; 2015; 10(11):e0142273. PubMed ID: 26562020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF mutations in conjunctival melanoma.
    Gear H; Williams H; Kemp EG; Roberts F
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2484-8. PubMed ID: 15277467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF mutation detection and identification by cycling temperature capillary electrophoresis.
    Hinselwood DC; Abrahamsen TW; Ekstrøm PO
    Electrophoresis; 2005 Jun; 26(13):2553-61. PubMed ID: 15948220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
    Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-Scarrà G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G;
    J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes.
    Lake SL; Jmor F; Dopierala J; Taktak AF; Coupland SE; Damato BE
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5598-604. PubMed ID: 21693616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
    Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
    Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
    Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low incidence of minor BRAF V600 mutation-positive subclones in primary and metastatic melanoma determined by sensitive and quantitative real-time PCR.
    Kristensen T; Clemmensen O; Hoejberg L
    J Mol Diagn; 2013 May; 15(3):355-61. PubMed ID: 23499336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.